{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:29:06Z","timestamp":1794047346814,"version":"4.8.0"},"reference-count":13,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"10","license":[{"start":{"date-parts":[[2020,2,13]],"date-time":"2020-02-13T00:00:00Z","timestamp":1581552000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"DOI":"10.3324\/haematol.2019.243170","type":"journal-article","created":{"date-parts":[[2020,2,13]],"date-time":"2020-02-13T11:09:15Z","timestamp":1581592155000},"page":"e512","source":"Crossref","is-referenced-by-count":5,"title":["Brentuximab vedotin in the treatment of elderly Hodgkin lymphoma patients at first relapse or with primary refractory disease: a phase II study of FIL ONLUS"],"prefix":"10.3324","volume":"105","author":[{"family":"Vittorio Stefoni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Miriam Marangon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Alessandro Re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Arben Lleshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Maurizio Bonfichi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Antonello Pinto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Nicola Bianchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Cinzia Pellegrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Lisa Argnani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Pier Luigi Zinzani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2020,2,13]]},"reference":[{"key":"12949","doi-asserted-by":"crossref","unstructured":"Brenner H, Gondos A, Pulte D. Ongoing improvement in long-term survival of patients with Hodgkin disease at all ages and recent catchup of older patients. Blood. 2008;111(6):2977-2983.","DOI":"10.1182\/blood-2007-10-115493"},{"key":"12950","doi-asserted-by":"crossref","unstructured":"Engert A, Ballova V, Haverkamp H, et al. Hodgkin's lymphoma in elderly patients: a comprehensive retrospective analysis from the German Hodgkin's Study Group. J Clin Oncol. 2005;23(22):5052-5060.","DOI":"10.1200\/JCO.2005.11.080"},{"key":"12951","unstructured":"Landgren O, Algernon C, Axdorph U, et al. Hodgkin's lymphoma in the elderly with special reference to type and intensity of chemotherapy in relation to prognosis. Haematologica. 2003;88(4):438-444."},{"key":"12952","doi-asserted-by":"crossref","unstructured":"Evens AM, Helenowski I, Ramsdale E, et al. A retrospective multicenter analysis of elderly Hodgkin lymphoma: outcomes and prognostic factors in the modern era. Blood. 2012;119(3):692-695.","DOI":"10.1182\/blood-2011-09-378414"},{"key":"12953","doi-asserted-by":"crossref","unstructured":"van Spronsen DJ, Janssen-Heijnen ML, Lemmens VE, Peters WG, Coebergh JW. Independent prognostic effect of co-morbidity in lymphoma patients: results of the population-based Eindhoven Cancer Registry. Eur J Cancer. 2005;41(7):1051-1057.","DOI":"10.1016\/j.ejca.2005.01.010"},{"key":"12954","doi-asserted-by":"crossref","unstructured":"B\u00f6ll B, Goergen H, Behringer K, et al. Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials. Blood. 2016;127(18):2189-2192.","DOI":"10.1182\/blood-2015-11-681064"},{"key":"12955","doi-asserted-by":"crossref","unstructured":"B\u00f6ll B, Goergen H, Arndt N, et al. Relapsed Hodgkin lymphoma in older patients: a comprehensive analysis from the German Hodgkin Study Group. J Clin Oncol. 2013;31(35):4431-4437.","DOI":"10.1200\/JCO.2013.49.8246"},{"key":"12956","doi-asserted-by":"crossref","unstructured":"Gopal AK, Bartlett NL, Forero-Torres A, et al. Brentuximab vedotin in patients aged 60 years or older with relapsed or refractory CD30-positive lymphomas: a retrospective evaluation of safety and efficacy. Leuk Lymphoma. 2014;55(10):2328-2334.","DOI":"10.3109\/10428194.2013.876496"},{"key":"12957","doi-asserted-by":"crossref","unstructured":"Br\u00f6ckelmann PJ, Zagadailov EA, Corman SL, et al. Brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma who are Ineligible for autologous stem cell transplant: A Germany and United Kingdom retrospective study. Eur J Haematol. 2017;99(6):553-558.","DOI":"10.1111\/ejh.12973"},{"key":"12958","doi-asserted-by":"crossref","unstructured":"Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25(5):579-586.","DOI":"10.1200\/JCO.2006.09.2403"},{"key":"12959","doi-asserted-by":"crossref","unstructured":"Forero-Torres A, Holkova B, Goldschmidt J, et al. Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older. Blood. 2015;126(26):2798-2804.","DOI":"10.1182\/blood-2015-06-644336"},{"key":"12960","doi-asserted-by":"crossref","unstructured":"Younes A, Gopal AK, Smith SE, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol. 2012;30(18):2183-2189.","DOI":"10.1200\/JCO.2011.38.0410"},{"key":"12961","doi-asserted-by":"crossref","unstructured":"Yasenchak CA, Bordoni R, Yazbeck V, et al. Phase 2 study of frontline brentuximab vedotin plus nivolumab in patients with Hodgkin lymphoma aged \u226560 years. Blood. 2019;134(Suppl 1):237.","DOI":"10.1182\/blood-2019-124866"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/9653\/70580","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/9653\/70581","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/9653\/70580","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T09:56:03Z","timestamp":1794045363000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/9653"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,13]]},"references-count":13,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2020,10,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2019.243170","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2,13]]}}}